The Pharma 50 has a new company sitting at the top: Eli Lilly, which last year was in the ninth slot. The next question is how long it can stay there, because pharma sector leadership is, historically, something of a revolving door. Right now, Lilly’s lead is razor thin. Just $170 million separated Eli Lilly’s…
A world tour of Big Pharma: Mapping the HQs of the top 50 companies
Almost half (22) of the top 50 pharmaceutical companies were based in the U.S., with a strong concentration in the Northeast region, particularly in New Jersey, New York and Massachusetts. The biggest U.S. firms in this year’s ranking were Merck & Co. (1), Pfizer (2) and Johnson & Johnson (3), respectively — all with headquarters…
A glimpse at Big Pharma’s upper echelon in the first three quarters of 2023
In 2023, demand for GLP-1 receptor agonists such as Lilly’s tirzepatitde and Novo Nordisk’s semaglutide surged just as demand for COVID-19 therapies waned. As a result, Novo Nordisk had 33% growth at constant exchange rates over the first nine months of the year. Similarly, Lilly experienced a 37% jump in revenue in the third quarter,…


